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Summary
Objective: Analysis of hepatitis delta virus (HDV) isolates from around the world has indicated
that there are at least three phylogenetically distinct genotypes with different geographic
distributions. The aim of this study was to determine the distribution of HDV genotypes by direct
sequencing in patients with chronic delta hepatitis in Izmir, Turkey.
Design and methods: Serum samples from 32 chronic hepatitis patients (21 males, 11 females;
mean age 44.2 years, range 23—70 years) with anti-delta positivity were analyzed for hepatitis B
and C serologies. After reverse transcription, cDNA of partial delta antigen was amplified by in-
house nested PCR. The products of the HDV PCR were bidirectionally sequenced with internal
primers using Big Dye Terminator DNA Sequencing Kit (Applied Biosystems, CA, USA) and ABI Prism
310 Genetic Analyzer (Perkin Elmer, USA). Nucleotide sequences of HDV were compared with
previously reported sequences and aligned by using ClustalW (1.82).
Results: HDV-RNA was positive in 26 (81.3%) of 32 anti-delta positive samples. Comparison of the
HDVsequenceswithpublishedsequencesofHDVgenotypes I, II,and III indicatedthatallwereclosely
related to HDV genotype I isolates. Similarity among isolated sequences ranged from 84% to 96%.
Conclusion: HDV genotyping was successfully performed by direct sequencing of the amplicons
obtained from routine HDV-RNA screening PCR tests. All of the HDV isolates from the chronic delta
hepatitis patients included in this study were found to be genotype I.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Hepatitis delta virus (HDV) is a defective RNA virus that
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doi:10.1016/j.ijid.2005.10.012for replication.1 Disease associated with both acute and
chronic HDV infection is usually more severe than that due
to HBV infection alone.2
Recent improvements in molecular techniques have pro-
vided increased understanding of the natural course of HDV
infection. These advances have enhanced the clinician’s
ability to evaluate the stage of HDV infection, response to
therapy, and occurrence of reinfection after liver transplan-
tation.3Published by Elsevier Ltd. All rights reserved.
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world has indicated that there are at least three phylogen-
etically distinct genotypes with different geographic distri-
butions. HDV genotyping is based on direct sequencing or
restriction fragment length polymorphism (RFLP) analysis of
reverse transcription (RT) products of the HDV genomes from
patients. Genotype I is the most widespread geographically,
having been identified in isolates from North America, Eur-
ope, and the Middle East. Genotype II has been found in East
Asia. Genotype III is found exclusively in South America.4
Divergence in nucleotide sequences ranges from 27% to 34%
and in amino acid sequences is 30% among different geno-
types.5 A new study suggests that the genetic variability of
HDV is much more complex than was previously thought and
the genus includes at least seven clades.6 The clinical pattern
resulting from infection with HDV genotype I is very variable,
ranging frommild to severe disease. Genotype II usually gives
rise to a milder hepatitis, while genotype III appears to lead
more often to fulminant hepatitis.7
Turkey is in the intermediately endemic region and anti-
delta seroprevalance was found to be 6.7% in 716 hepatitis B
surface antigen (HBsAg) positive samples tested in the Clin-
ical Virology Laboratory of Ege University Hospital, Izmir.8
The aim of this study was to determine HDV genotypes and
analyze the sequences encoding the C-terminal half of the
delta antigen by direct sequencing of isolates from patients
with chronic delta hepatitis.
Materials and methods
Serum samples from 32 patients (21 males, 11 females; mean
age 44.2 years, range 23—70 years) with chronic delta hepa-
titis were analyzed for hepatitis B, D, and C serological
markers including hepatitis B surface antigen (HBsAg), hepa-
titis B e antigen (HBeAg), anti-HBe, anti-HCV (BioMerieux,
France), and anti-delta (Diasorin, Italy) by micro-enzyme
immunoassay method. HBV-DNAwas tested by a quantitative
PCR assay according to the manufacturer’s instructions (HBV
Monitor, Roche Molecular Diagnostics, NJ, USA).
HDV-RNA was extracted from 150 mL of serum samples by
Nucleospin RNA virus extraction kit (Macherey-Nagel, Ger-
many) and 50-mL eluate was prepared. The RNA pellet was
reverse transcribed to complementary DNA (cDNA) using
random hexanucleotide mix and M-MuVL in a final volume
of 20 mL. The mixture was incubated in a thermal cycler at
42 8C for one hour. Ten microliters of the resultant cDNA
preparation were added to 40 mL of a PCR solution containing
25 pmol of external sense primer (nucleotides (nt) 858—881)Table 1 HBeAg/anti-HBe status and HBV-DNA levels of HDV-RNA p
HDV-RNA positive patients)
Total HBV-DNA level
<200
HBeAg+, anti-HBe 5 —
HBeAg, anti-HBe+ 18 8
HBeAg, anti-HBe 2 2
HBeAg+, anti-HBe+ 1 —
Total 26 1050 GCC CAG GTC GGA CCG CGA GGA GGT 30 and external
antisense primer (nt 1289—1312) 50 ACA AGG AGA GGC AGG
ATC ACC GAC 30, and 2U Taq polymerase. The mixture was
amplified by 35 cycles of PCR (94 8C for 1 min, 55 8C for 1 min,
72 8C for 1 min) followed by a 7-min extension at 72 8C. Five
microliters of the product were used for the second round
PCR using 25 pmol internal sense primer (nt 883—906) 50 GAG
ATG CCA TGC CGA CCC GAA GAG 30 and internal antisense
primer (nt 1265—1288) 50 GAA GGA AGG CCC TCG AGA ACA
AGA 30 set with the same conditions as the first PCR. PCR
working precautions were strictly followed and negative
controls were added between samples. Products were ana-
lyzed by electrophoresis on 1% agarose gel and the expected
359 base pair length was confirmed.9
The products of the HDV PCR were sequenced bidirec-
tionally with internal primers using Big Dye Terminator DNA
Sequencing Kit (Applied Biosystems CA, USA) and ABI Prism
310 genetic analyzer (Perkin Elmer, USA). Sequences
obtained from the sera of the 26 patients with HDV infec-
tion and 17 sequences representing all types of HDV
from the database of GenBank/EMBL/DDBJ, were aligned
by ClustalW (1.82). Phylogenetic comparison was
done by TREECON version 1.3b after bootstrapping 100
replicates.10
Nucleotide sequence accession numbers of
the reference HDV sequences
The accession numbers of the reference sequences used were
as follows: Tw-2b, AF018077; dFr-48, AJ583871 (Camer-
oon); DFr-644, AJ583882 (Congo), dFr-47, AJ583870 (Gui-
nea); L22063 (Peru); AF251367 (Venezuela); X60193
(Japan); AY261457 (Tw-2a); AF008372 (France);
AF008371 (USA); AF008417 (Italy); U81989 (Ethiopia);
U81988 (Somalia IC); AF008875 (Egypt); AF008320
(Greece); AF008309 (Albania); AF008319 (Romania).
The sequences of 26 patients in this study are available at
GenBank with accession numbers from DQ223507 to
DQ223532.
Results
HDV-RNA was positive in 26 (81.3%) of 32 anti-delta positive
samples. All the samples were HBsAg positive and anti-HCV
negative. The HBV-DNA levels of HDV-RNA positive patients,
and HBeAg and anti-HBe status of the patients are summar-
ized in Table 1. Since clinical information and data about
therapy and duration of therapy could not be obtained fromositive patients (HBV-DNA levels were determined for 22 of 26
(copy/mL)
200—200 000 >200 000 Unknown
1 2 2
7 1 2
— — —
— 1 —
8 4 4
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was not evaluated. Comparison of the HDV sequences with
the reported sequences from HDV genotypes I, II, and III
indicated that all were closely related to HDV genotype I
isolates. The phylogenetic tree of 26 sequences with 17
references by TREECON version 1.3b is shown in Figure 1.10
Nucleotide similarity among the 26 isolated sequences
ranged from 84% to 97% (mean 89.8%). Amino acid sequence
similarity was found to be in the range of 75—95% (mean
85.8%). By pair-wise comparison, nucleotide similarity ran-Figure 1 Phylogenetic tree of 26 sequences wiged from 82% to 96% (mean 86.9%) in the hepatitis delta
antigen (HDAg) segment with the GenBank database type I
sequences (AF008309, AF008320, AF008319, AF008375,
AF008372, AF008371, AF008417, U81989, U81988), the
U81988 Somalia IC isolate being the least, and Albania
AF008309 isolate the most, similar. When compared with
previously reported sequences from Turkey (accession num-
bers AY148019—AY148027) nucleotide divergence was
found to be 9.1% (3.9—14.5). Suggested representatives of
the new clades, Tw-2b, dFr-47, dFr-48, and dFr-644, wereth 17 references by TREECON version 1.3b.10
HDV genotypes in patients with chronic hepatitis in Turkey 61also included in our study. By pair-wise comparison, nucleo-
tide similarity of our isolates with Tw-2b, dFr-47, dFr-48, and
dFr-644 ranged between 75% and 81% (mean 75.4%), 71% and
78% (mean 74.9%), 71% and 79% (mean 75.5%), and 70% and
76% (mean 74.1%), respectively. Nucleotide similarity among
the isolated sequences and GenBank sequences is shown in
Supplementary data in Appendix A.
Discussion
It is known that HDV infection is highly prevalent in patients
with chronic HBV infection in Turkey. Overall anti-HDV ser-
opositivity in Turkey ranges between 2.9% and 33%; in asymp-
tomatic HBsAg carriers it is 0—11.2% and in patients with
chronic hepatitis it is 6.8—53.4%.11—13
In a study in which the epidemiology and clinical pre-
sentation of HDV in Turkey were studied, the prevalence of
HDV infection was significantly higher in patients with
chronic liver disease than in asymptomatic carriers of HBsAg.
The frequency of ‘severe’ or fulminant hepatitis was similar
in HBV infected and HBV/HDV coinfected individuals. The
frequency of biphasic hepatitis was significantly higher in
the latter group than in those with classical hepatitis B.14
Since genotypes may influence the clinical outcome of the
disease and display geographic dissimilarities, it seems that it
is important to determine the occurrence of diverse geno-
types in a population, which may contribute to the clinical
setting. Reports on HDV genotypes in Turkey are limited. In a
study performed on different isolates from various countries,
five isolates from Turkey were found to be genotype I.15 In a
recent study from Turkey, a typing method of HDV, based on
RFLP patterns of amplified HDAg of HDV genome was used for
HDV-RNA typing. RFLP analysis revealed an HDV genotype I
pattern in all patients. In the aforementioned report, for 13
patients, direct sequencing was also performed, and these
data were used for phylogenetic analysis.16
In our study, the genotype assignment was based on the
analysis of the sequences that corresponded to nucleotides
between 906 and 1265, and included sequences encoding
the C-terminal half of HDAg. Sequences encoding the C-
terminal half of the HDAg were up to 15% variable among
genotype I isolates.9 In another study on geographic dis-
tribution and genetic variability of hepatitis delta virus
genotype I, sequence divergence among genotype I isolates
from different countries ranged from 3.1% to 13.4%.15 In a
study from Turkey, by pair-wise comparison, isolates dif-
fered in the HDAg from other GenBank type I sequences by
6  1.0% (range 1—7.1%) in the HDAg segment (nucleotides
between 904 and 1210). The mean nucleotide divergence of
HDV RNA sequences from 13 patients was reported as
2.5  0.6%.16 In our isolates, a longer HDAg segment
(nucleotides between 923 and 1262) was analyzed and by
pair-wise comparison, nucleotide similarity among isolated
sequences ranged from 84% to 97% (mean 89.8%). The
number of analyzed sequences is greater than the previous
report, which may account for the greater nucleotide
divergence in the study. Greater nucleotide difference
may also be due to the length of the analyzed segment
which is 33 base pairs longer than the previous one with
different starting and ending points (nt 904—1210 vs. nt
923—1262).In a study on molecular phylogenetic analysis of delta
virus, HDV genetic variability was extended to at least seven
major clades, bringing the variability of the virus closer to
that of HBV. In this study, the sequences from the serotype II B
complex form a distinct clade (proposed as HDV 4), and dFr-
47, dFr-48, and dFr-644 are considered as the representatives
of the new African clades.6 Suggested representatives of the
new clades were also included in our phylogenetic analysis.
By pair-wise comparison, nucleotide similarity of our isolates
with Tw-2b, dFr-47, dFr48, and dFr-644 ranged between 75%
and 81% (mean 75.4%), 71% and 78% (mean 74.9%), 71% and
79% (mean 75.5%), and 70% and 76% (mean 74.1%), respec-
tively, showing that they are not related to these isolates that
represent the new clades.
In this study HDV genotyping was successfully performed
by direct sequencing of the amplicons obtained from routine
HDV-RNA screening PCR tests. All of the HDV isolates from the
chronic delta hepatitis patients included in this study were
found to be genotype I. HDV type I seems to be the unique
genotype found in the Turkish population, which is an
expected finding in agreement with similar epidemiological
studies from the Mediterranean region and confirms pre-
viously published data.
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